A Phase 2 interventional study of bevacizumab [Avastin] and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-10.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 120th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2007, is one of 157 in phase 2, and was the 144th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 19 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 27 under way, 13 of them phase 3. Of 194 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 119th largest by enrollment of the 170 interventional ones that give a count, is one of 12 that started in 2007, is one of 65 in phase 2, and was the 31st registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of a combination of Avastin and docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable breast cancer. Patients will receive 4 x 3 week cycles of chemotherapy with doxorubicin (60mg/m2 iv on day 1 of each cycle) and cyclophosphamide (600mg/m2 iv on day 1 of each cycle). They will then receive 4 x 3 week cycles of docetaxel (75mg/m2 on day 1 of each cycle) in combination with Avastin (15mg/kg on day 1 of each cycle). The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: Docetaxel · Drug: Standard chemotherapy
15mg/kg iv on day 1 of each 3 week cycle
75mg/m2 iv on day 1 of each 3 week cycle
As prescribed
Percentage of Participants With Pathological Complete Response (pCR)
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA). It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
Time frame: After Week 24 (surgery)
Percentage of Participants With Objective Clinical Response
Overall clinical response is the best response obtained through physical examination and/or radiological tests after completion of chemotherapy cycles. The percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and was categorized as clinical response (CR+PR) or clinical benefit (CR+PR+ no change \[NC\]). Per RECIST, CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.
Time frame: Within 28 days of enrollment, Weeks 12 and 24
Percentage of Participants With Breast-Conserving Surgery
Breast-conserving surgery was defined as lumpectomy + lymphadenectomy (LA), segmentectomy + LA, quadrantectomy + LA, or other (including sentinal node extirpation tumorectomy).
Time frame: Week 24
Percentage of Participants With pCR by Proliferation of Ki67
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Biomarker Ki67 proliferation was defined as low (less than \[\<\]15% ) and high (≥15%).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Kisspeptin (KISS1) Amplification
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by KISS1 Protein Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEFGR amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by VEGFR Protein Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Angiotension Protein Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Angiotensin protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by VEGFR Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pAKT gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by HIF Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. IGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by ENOS Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pMAPK gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. AGTR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by KISS1 Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
Percentage of Participants With pCR by RKISS1 Gene Expression
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. RKISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
Time frame: After Week 24 (surgery)
| Milestone | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Started | 72 |
| Completed | 61 |
| Not completed | 11 |
| Withdrew: Disease progression | 1 |
| Withdrew: Adverse event | 5 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Investigator criteria | 2 |
| Withdrew: Withdrawal by subject | 2 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA). It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) | 24.2 (14.5 to 36.4) |
Overall clinical response is the best response obtained through physical examination and/or radiological tests after completion of chemotherapy cycles. The percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) and was categorized as clinical response (CR+PR) or clinical benefit (CR+PR+ no change \[NC\]). Per RECIST, CR was defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met.
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| CR+PR | 88.9 (79.3 to 95.1) |
| CR+PR+NC | 98.6 (92.5 to 99.9) |
Breast-conserving surgery was defined as lumpectomy + lymphadenectomy (LA), segmentectomy + LA, quadrantectomy + LA, or other (including sentinal node extirpation tumorectomy).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Percentage of Participants With Breast-Conserving Surgery | 62.7 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Biomarker Ki67 proliferation was defined as low (less than \[\<\]15% ) and high (≥15%).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| High proliferative index (n=50) | 24.0 |
| Low proliferative index (n=15) | 13.3 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Anueploid (n=8) | 12.5 |
| Normal (n=13) | 30.77 |
| Amplification (n=2) | 50.0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| No expression (n=18) | 27.8 |
| Normal (n=3) | 66.7 |
| Augmented expression (n=4) | 50.0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEFGR amplification was defined as 1 (aneuploid), 2 (normal), 4 (amplification), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Anueploid (n=1) | 0 |
| Normal (n=18) | 33.3 |
| Amplification (n=4) | 0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| No expression (n=7) | 28.6 |
| Normal (n=5) | 40.0 |
| Augmented expression (n=10) | 20.0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| No expression (n=25) | 40.0 |
| Normal (n=8) | 12.5 |
| Augmented expression (n=5) | 60.0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| No expression (n=24) | 29.2 |
| Normal (n=10) | 40.0 |
| Augmented expression (n=4) | 25.0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. Angiotensin protein expression was defined as 0 (no expression), 1 (normal), 2 (augmented expression), or NE (not evaluated).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| No expression (n=14) | 7.1 |
| Normal (n=1) | 0.0 |
| Augmented expression (n=11) | 63.6 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=1) | 100.0 |
| Gene expression below housekeeping level (n=33) | 30.3 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. VEGFR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=7) | 0.0 |
| Gene expression below housekeeping level (n=27) | 40.7 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pAKT gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=0) | NA |
| Gene expression below housekeeping level (n=34) | 32.4 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. HIF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=9) | 44.4 |
| Gene expression below housekeeping level (n=25) | 28.0 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. IGF gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=0) | NA |
| Gene expression below housekeeping level (n=34) | 32.4 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. ENOS gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=1) | 0 |
| Gene expression below housekeeping level (n=33) | 33.3 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. pMAPK gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=30) | 33.3 |
| Gene expression equal to housekeeping level (n=1) | 0 |
| Gene expression below housekeeping level (n=3) | 33.3 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. AGTR gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=0) | NA |
| Gene expression below housekeeping level (n=33) | 30.3 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. KISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=1) | 0.0 |
| Gene expression below housekeeping level (n=33) | 33.3 |
The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria. It was only considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes. RKISS1 gene expression was defined as below the housekeeping reference level (\>0), above the housekeeping reference level (\<0), or equal to the housekeeping reference level (0).
| percentage of participants | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Gene expression above housekeeping level (n=0) | NA |
| Gene expression below housekeeping level (n=34) | 32.4 |
Collected over Adverse events (AEs) were reported from the day of informed consent to the last date of contact for all participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel | — | 13/72 (18.1%) | 71/72 (98.6%) |
| Event | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Febrile neutropaeniaInfections and infestations | 6/72 |
| Neutrophils/granulocytesBlood and lymphatic system disorders | 4/72 |
| Mucositis/stomatitisGastrointestinal disorders | 2/72 |
| Infection with normal absolute neutrophil count (ANC) or grade 1 or 2 neutrophilsInfections and infestations | 1/72 |
| VomitingGastrointestinal disorders | 1/72 |
| Event | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Fatigue (asthenia, lethargy, malaise)General disorders | 44/72 |
| Mucositis/stomatitisGastrointestinal disorders | 43/72 |
| NauseaGastrointestinal disorders | 43/72 |
| Hair loss/alopeciaSkin and subcutaneous tissue disorders | 36/72 |
| PainGeneral disorders | 36/72 |
| VomitingGastrointestinal disorders | 24/72 |
| DiarrhoeaGastrointestinal disorders | 17/72 |
| Infection with normal ANC or grade 1 or 2 neutrophilsInfections and infestations | 17/72 |
| ConstipationGastrointestinal disorders | 14/72 |
| FeverGeneral disorders | 14/72 |
Intent to Treat (ITT) Population: all participants included in the study.
| Age, Continuous(years) | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Mean | 47.22 ± 9.85 |
| Sex/Gender, Customized(participants) | Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel |
|---|---|
| Female | 72 |
The record gives a start of Dec 2007, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel